



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • **CIN :** L24233MP1985PLC002709

Date:14/11/2018

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	---

Sub: - Submission of Un-Audited Financial Results for the Quarter as well as half ended on 30th September, 2018 along with Limited Review Report and Statement of Assets and Liabilities as per Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

Ref: BSE Security Code: 524396; NSE Symbol : BIOFILCHEM; ISIN: INE829A01014

Dear Sir/Madam

Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are enclosing Unaudited Financial results along with Limited Review Report and Statement of assets and liabilities for the quarter as well as half year ended 30th September, 2018 duly approved by the Board of the Directors of the Company in their meeting held on today 14th Day of November, 2018.

Further, copy of Un-Audited Financial Statements and Limited Review Report shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.


The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. These results shall also be uploaded on the website of the Company i.e. www.biofilgroup.net and on the website of the Stock Exchanges at www.bseindia.com and www.nseindia.com


You are requested to take on record the above said financial results for your reference and record.

Thanking you,

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited


Ramesh Shah
Managing Director
DIN :- 00028819



Enclosure: Un-Audited Financial Results for the quarter as well as half year ended on 30th September, 2018.



Limited Review Report for the Six Months ended September 30, 2018

To,
The Board of Directors
Biofil Chemicals And Pharmaceuticals Limited
Indore (M.P.)

1. We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals And Pharmaceuticals Limited for the six month ended 30th September, 2018**. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "review of interim financial information performed by Independent Auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards as specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Gupta
Chartered Accountants
Firm Reg. No. 0061790

CA. Sunil Maheshwari
Partner
M: No. 403346



Place: Indore
Date: 14th November, 2018

Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709


Email : bcplcompliance@gmail.com

Tel : 0731-2723016

UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th Sept , 2018

(Amount in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the Quarter & Half Year ended 30th Sep 2018							
	Particulars	Quarter Ended			Half Year Ended		Audited for the year ended March 31 2018
		3 months ended (30/09/2018)	Preceding 3 months ended (30/06/2018)	Corresponding 3 months ended in the previous year (30/09/2017)	Year to date figures for current period ended (30/09/2018)	Year to date figures for the previous year ended (30/09/2017)	
		Un- audited	Un- audited	Un- audited	Un- audited	Un-audited	Audited
I	Revenue from Operation	213.60	422.40	83.36	636.01	789.71	1236.00
II	Other Income	2.00	1.66	0.70	3.66	1.02	10.07
III	Total Revenue (I + II)	215.61	424.07	84.05	639.67	790.72	1246.07
IV	Expenses						
	(a) Cost of materials consumed	20.52	12.29	12.20	32.81	25.73	77.75
	(b) Purchases of stock-in-trade	864.49	413.14	35.05	1277.63	698.80	991.06
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(738.74)	(59.39)	(4.20)	(798.14)	(6.40)	(91.70)
	(d) Employee benefits expense	20.19	21.19	17.33	41.39	23.02	72.93
	(e) Finance Cost	3.92	3.86	3.86	7.79	7.61	15.06
	(f) Depreciation and Amortisation Expense	7.11	7.49	7.11	14.60	14.22	29.63
	(g) Other expenses	27.64	19.08	5.49	46.72	10.77	92.53
	Total expenses (IV)	205.13	417.66	76.85	622.79	773.75	1187.25
V	Profit (Loss) before exceptional items and tax (III-IV)	10.48	6.41	7.21	16.88	16.97	58.82
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit (Loss) before tax (V - VI)	10.48	6.41	7.21	16.88	16.97	58.82
VIII	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	11.75
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operation (VII-VIII)	10.48	6.41	7.21	16.88	16.97	47.07
X	Profit (Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit (Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit (Loss) for the period (IX+XII)	10.48	6.41	7.21	16.88	16.97	47.07
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
	A) (i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss						
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss						
	c) Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII + XIV)	10.48	6.41	7.21	16.88	16.97	47.07
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII	Other Equity excluding Revaluation Reserve as per balance Sheet						
XVIII	Earnings per equity shares: (not annualised)						
	(1) Basic (Rs)	0.06	0.04	0.04	0.10	0.10	0.29
	(2) Diluted (Rs)	0.06	0.04	0.04	0.10	0.10	0.29



1. The standalone unaudited financial results of Biofil Chemicals & Pharmaceuticals Ltd, ("the company" for the quarter ended Septmeber 30, 2018 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on Novmeber 14, 2018.

2. The Limited Review of the financial Results of the Quarter ended 30th September 2018 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, has been carried out bt the Statutory Auditors.

3. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- I. Pharma Product
- II. Chemicals Division
- III. Plastic Division

4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.


6. The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors


7. The revenue for the half year ended 30th September 2018 is not comparable as it is reported net of Goods and Service Tax (GST).

Date : 14/11/2018

Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited


RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)



BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN NO. L24233MP1985PLC002709

Email : bcplcompliance@gmail.com

Tel : 0731-2723016

UN-AUDITED FINANCIAL STATEMENT OF ASSETS AND LIABILITIES AS AT 30-09-2018


(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		Unaudited	Audited
Particulars	As at 30/09/2018	As at 31/03/2018	
A ASSETS			
1 Non-current assets:			
(a) Property, Plant & Equipment	947.78	924.68	
(b) Capital work in Progress			
(c) Other Intangible Assets			
(d) Financial Assets:			
i. Investments			
ii. Other Financial Assets			
(e) Other Non- Current Assets			
Sub-total - Non-current assets	947.78	924.68	
2 Current assets			
(a) Inventories	740.74	102.48	
(b) Financial Assets:			
(i) Trade receivables	697.22	1298.08	
(ii) Cash and cash equivalents	3.30	10.71	
(iii) Bank balances other than (ii) above	14.59	26.74	
(iv) Loans	23.93	29.15	
(v) Other Financial Assets			
(c) Current Tax Assest (Net)			
(d) other Currents Assets	167.02	23.61	
Sub-total - Current assets			
TOTAL - ASSETS	2594.59	2415.46	
B EQUITY AND LIABILITIES			
1 Equity			
(i) Equity Share Capital	1627.38	1627.38	
(ii) Other Equity	-323.87	-310.65	
Sub-total- Equity	1303.51	1316.73	
LIABILITIES			
2 Non-current Liabilities :			
a Financial Liabilities			
(i) Borrowings			
(ii) other Financial Liabilities			
b Provisions			
c Deferred tax liabilities (net)			
d Other Non-current Liabilities			
Sub-total - Non-current liabilities	1303.51	1316.73	
3 Current liabilities			
a Financial Liabilities			
(i) Borrowings	162.80	155.86	
(ii) Trade Payables	1127.05	914.17	
(iii) other Financial Liabilities			
b Other Current Liabilities			
c Provisions	1.24	28.71	
d Current Tax Liabilities (Net)			
Sub-total - Current liabilities	1291.08	1098.74	
TOTAL - EQUITY AND LIABILITIES	2594.59	2415.46	

Date : 14/11/2018
Place : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
(DIN NO. 00028819)



Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709

Email : bcplcompliance@gmail.com

Tel : 0731-2723016

Segmentwise Revenue, Results an Capital Employed for year ended 30th Sept 2018

(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Half Year Ended		31 March
		Sep 30 ,	June 30 ,	Sep 30 ,	Sep 30 ,	Sep 30 ,	
		2018	2018	2017	2018	2017	
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
		30.09.2018	30-06-2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
1	Segment Revenue						
	Pharma Unit	147.85	381.43	36.22	529.28	715.52	1,053.13
	Chemicals Division	65.75	40.98	47.14	106.73	71.35	180.02
	Plastic Division	0.00	2.84	0.00	2.84	2.84	2.84
	Other	2.00	1.66	0.70	3.66	1.02	10.07
	Gross Turnover	215.61	426.91	84.05	642.52	790.72	1,246.07
2	Segment Results						
	Pharma Unit	12.90	4.62	1.52	17.52	17.23	56.31
	Chemicals Division	5.20	6.69	13.19	11.89	11.90	26.91
	Plastic Division	(3.88)	(1.07)	(3.75)	(4.95)	(4.66)	(4.01)
	Other		0.00		0.00	0.00	(8.41)
	Total Segment Profit Before Tax	14.23	10.24	10.96	24.46	24.47	70.79
	Interest Income		0.00		0.00	0.00	3.03
	Interest Expenses	3.75	3.83	3.75	7.58	7.50	15.00
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	10.48	6.41	7.21	16.88	16.97	58.82
	Provision for current tax	0.00	0.00	0.00	0.00		11.30
	Item Related Earlier Year	0.00	0.00	0.00	0.00		0.45
	Profit After Tax	10.48	6.41	7.21	16.88	16.97	47.07
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	1,601.67	1,262.13	1,814.50	1,601.67	1,814.50	1,485.86
	Chemicals Division	959.84	878.73	836.44	959.84	836.44	866.71
	Plastic Division	120.70	59.39	67.88	120.70	67.88	62.89
	Other						
	Total (A)	2,682.21	2,200.26	2,718.81	2,682.21	2,718.81	2,415.46
	Segment Liabilities (B)						
	Pharma Division	1,079.07	700.18	1,267.78	1,079.07	1,267.78	898.26
	Chemicals Division	64.29	31.65	55.95	64.29	55.95	41.52
	Plastic Division	166.03	162.54	148.86	166.03	148.86	158.96
	Other				0.00	0.00	
	Total (B)	1,309.39	894.36	1,472.59	1,309.39	1,472.59	1,098.74
	Total Capital Employed (Segment Assets- Segment Liabilities)						
	Pharma Division	522.60	561.96	546.72	522.60	546.72	587.60
	Chemicals Division	895.56	847.08	780.49	895.56	780.49	825.19
	Plastic Division	(45.33)	(103.15)	(80.99)	(45.33)	(80.99)	(96.07)
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,372.83	1,305.89	1,246.22	1,372.83	1,246.22	1,316.73

DATE : 14-11-2018
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR

DIN: 00028819

